Johanna Mercier Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Key Points

• Johanna Mercier, an insider at Gilead Sciences, sold 3,000 shares at an average price of $113.57, totaling $340,710, which resulted in a 2.58% decrease in her ownership of the stock.
• Gilead Sciences reported an EPS of $2.01 for the last quarter, exceeding expectations, with a revenue of $7.08 billion, marking a 1.4% year-over-year increase.
• The company announced a quarterly dividend of $0.79 per share, with a dividend yield of 2.9%, payable to investors of record on September 15th.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the transaction, the insider owned 113,193 shares of the company's stock, valued at $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Johanna Mercier also recently made the following trade(s):

• On Friday, August 15th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00.
• On Tuesday, July 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $111.03, for a total value of $333,090.00.
• On Tuesday, July 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $111.03, for a total value of $333,090.00.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $1.68 during trading hours on Tuesday, hitting $110.86. The company's stock had a trading volume of 5,457,797 shares, compared to its average volume of 8,084,145. Gilead Sciences, Inc. has a 12 month low of $81.83 and a 12 month high of $121.83. The company's 50 day simple moving average is $114.05 and its two-hundred day simple moving average is $110.06. The company has a market cap of $137.56 billion, a P/E ratio of 22.08, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the company earned $2.01 EPS. Gilead Sciences's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Valeo Financial Advisors LLC lifted its position in shares of Gilead Sciences by 26.9% during the 2nd quarter. Valeo Financial Advisors LLC now owns 13,278 shares of the biopharmaceutical company's stock valued at $1,472,000 after buying an additional 2,811 shares in the last quarter. NWF Advisory Services Inc. lifted its holdings in Gilead Sciences by 16.0% in the 2nd quarter. NWF Advisory Services Inc. now owns 2,162 shares of the biopharmaceutical company's stock worth $240,000 after purchasing an additional 299 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in Gilead Sciences by 3.6% in the 2nd quarter. Osaic Holdings Inc. now owns 204,115 shares of the biopharmaceutical company's stock worth $22,650,000 after purchasing an additional 7,166 shares in the last quarter. Total Investment Management Inc. purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $61,000. Finally, Centaurus Financial Inc. lifted its holdings in Gilead Sciences by 14.4% in the 2nd quarter. Centaurus Financial Inc. now owns 5,824 shares of the biopharmaceutical company's stock worth $646,000 after purchasing an additional 731 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday. UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Finally, Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $116.04.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.